Xeomin expected to drive down botulinum toxin prices when it reaches market
When it enters the U.S. market, Xeomin is expected to have a unit-to-unit equivalence to Botox, the standard aesthetic toxin in dermatology practices for years.
Current off-label use hasn’t shown any particular clinical advantage for Xeomin (incobotulinumtoxinA, Merz) over Botox (onabotulinumtoxinA, Allergan) or Dysport (abobotulinumtoxinA, Medicis), but the new toxin will broaden clinicians’ aesthetic options and may spur price competition in the U.S.
The unit-to-unit equivalence to Botox is one of Xeomin’s purported advantages over Dysport, says W. Philip Werschler, M.D., F.A.A.D., F.A.A.C.S., assistant clinical professor of medicine/dermatology, University of Washington, Seattle.
“This is one of the differences between Xeomin and Dysport, because Dysport does not have an accepted unit-to-unit conversion factor across all dosing ranges vis-à-vis Botox,” Dr. Werschler says.
Read the full original article at http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Xeomin-expected-to-drive-down-botulinum-toxin-pric/ArticleStandard/Article/detail/728789?contextCategoryId=40160
Source: July 1, 2011 for Dermatology Times at http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Xeomin-expected-to-drive-down-botulinum-toxin-pric/ArticleStandard/Article/detail/728789?contextCategoryId=40160
